Bergenbio AS, of Bergen, Norway, said clinical data from its lead product candidate BGB324, a first-in-class selective Axl kinase inhibitor demonstrated the clinical activity, tolerability and mechanism-of-action of BGB324 in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).